Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thalamus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Thalamus. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-002219-69 Sponsor Protocol Number: CHUBX2019/49 Start Date*: 2021-07-19
    Sponsor Name:CHU de Bordeaux
    Full Title: Long-term iron chelation in the prevention of secondary degeneration after cerebral infarction
    Medical condition: Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000908-15 Sponsor Protocol Number: IMI2-PainCare-BioPain-RCT4 Start Date*: 2019-09-24
    Sponsor Name:Aarhus University
    Full Title: A randomized, double-blind, placebo-controlled, cross-over trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing observed by...
    Medical condition: Healthy volunteers (intended indication: pain)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10033371 Pain PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001584-23 Sponsor Protocol Number: 7605 Start Date*: 2018-10-30
    Sponsor Name:University Hospital of Montpellier
    Full Title: "Microglial Activation in Narcolepsy Type 1: Positron Emission Tomography (PET) Study in [18F] DPA-714"
    Medical condition: To study in vivo microglial activation by PET [18F] DPA-714 in NT1 patients with recent evolution (appearance of the first symptoms - somnolence and cataplexy-less than 2 years ago) compared with c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023861-23 Sponsor Protocol Number: EPU P61 Start Date*: 2011-01-31
    Sponsor Name:Maastricht University
    Full Title: The effect of P-glycoprotein transport inhibition on brainmechanisms of sedation and cognitive impairment following antihistamines in healthy volunteers
    Medical condition: To assess the effects of inhibition of the P-glycoproteine transporter (by verapamil 120 mg) on cetirizine 15 mg in healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001079-39 Sponsor Protocol Number: 019/06 Start Date*: 2006-07-27
    Sponsor Name:Universitätsklinikum Bonn; Klinik und Poliklinik für Psychiatrie und Psychotherapie
    Full Title: Interozeptive Aufmerksamkeit, Hitze-Schwelle und körperliche Symptome bei Patienten mit einer depressiven Episode, vor und nach Behandlung mit Duloxetin. Eine Pilotstudie mittels funktioneller Mag...
    Medical condition: Diagnose einer „Major Depression“ (DSM-IV: 296.xx). Der Gesamtscore der Hamilton-Depressionsskala-17 muß mindestens 15 betragen. Zudem müssen die Patienten unter Schmerzsymptomen leiden. Dieses Kri...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006219-28 Sponsor Protocol Number: MRSI Start Date*: 2022-02-24
    Sponsor Name:Medical University Innsbruck
    Full Title: MR-Spectroscopy: Investigating neurochemical changes in brain metabolism in migraineurs before and after CGRPAntibody treatment – a randomized, controlled, open-label trial
    Medical condition: Episodic migraine
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003128-19 Sponsor Protocol Number: BiCS2019 Start Date*: 2019-11-27
    Sponsor Name:Psykiatrisk Center Glostrup
    Full Title: Biomarkers in Clozapine-responding Schizophrenia
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10009134 Chronic schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003750-89 Sponsor Protocol Number: KKS-186 Start Date*: 2013-02-14
    Sponsor Name:Philipps-University Marburg
    Full Title: A placebo-controlled, double blind, randomised trial with crossover-design investigating the effect of oxytocin nasal spray on neuronal processes of empathy
    Medical condition: high-functioning autism spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F 84.1)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10021737 Infantile autism LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001261-42 Sponsor Protocol Number: 3002 Start Date*: 2006-05-18
    Sponsor Name:Evotec NeuroSciences GmbH
    Full Title: Assessment of Inhibition of Brain MAO-B by EVT 301 after Repeated Dosing to Steady-state in Patients with Alzheimer’s Disease and in Elderly Control Subjects
    Medical condition: Subjects with probable Alzheimer's Disease and healthy voulunteers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-002151-10 Sponsor Protocol Number: NEUROPROTECTpost-CA Start Date*: 2015-08-07
    Sponsor Name:UZ Leuven
    Full Title: Neuroprotective goal directed hemodynamic optimization in post-cardiac arrest patients: a randomized controlled trial (the NEUROPROTECT post-CA trial)
    Medical condition: post-cardiac arrest patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10047283 Ventricular arrhythmias and cardiac arrest HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002636-16 Sponsor Protocol Number: VUMC-ANW-MS-GG-062017 Start Date*: 2017-10-09
    Sponsor Name:VU University medical center Amsterdam
    Full Title: Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate
    Medical condition: Multiple Sclerosis (MS). And specifically cognitive problems in MS.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002648-10 Sponsor Protocol Number: 7109 Start Date*: 2019-04-15
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: TestOsterone TreatmEnt on neuroprotection and Myelin repair in Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004579-37 Sponsor Protocol Number: MZ12-PCP-PalenicekTomas-A Start Date*: 2014-06-18
    Sponsor Name:National Institute of Mental Health
    Full Title: Animal and human serotonergic model of schizophrenia: validity evaluated by qEEG and fMRI
    Medical condition: Inclusion criteria: a) Men and women at age between 28 and 65 years b) healthy volunteers with negative psychiatric history (severe mental illnesses that meet the criteria of ICD 10 F0.X - F99.X) ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000064-21 Sponsor Protocol Number: TPN-101-AGS-201 Start Date*: 2022-09-20
    Sponsor Name:Transposon Therapeutics Inc
    Full Title: A Phase 2a Study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
    Medical condition: Aicardi-Goutières Syndrome (AGS)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10010331 - Congenital, familial and genetic disorders 10083189 Aicardi-Goutieres syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005738-23 Sponsor Protocol Number: CBAF312X2207 Start Date*: 2018-06-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, patient and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 in patients with stroke due to intracerebral hemorrhage (ICH)
    Medical condition: Intracerebral Hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10022754 Intracerebral hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002502-74 Sponsor Protocol Number: NEU-01-02-01 Start Date*: 2012-02-14
    Sponsor Name:Neurophyxia B.V.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of 2-iminobiotin (2-IB) in neonates with gestational...
    Medical condition: Perinatal asphyxia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10004943 Birth asphyxia LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003500 Asphyxia neonatal LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003144-23 Sponsor Protocol Number: 2017/81 Start Date*: 2018-09-05
    Sponsor Name:University of Liège [...]
    1. University of Liège
    2. CHU Liège
    Full Title: Treating severe brain-injured patients with apomorphine : a behavioural and neuroimaging study
    Medical condition: Disorders of consciousness
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003299-17 Sponsor Protocol Number: 22-1005-CALCIFADE Start Date*: 2023-03-20
    Sponsor Name:University Medical Center Utrecht
    Full Title: A randomized, placebo-controlled, double blind trial to study the effects of Etidronate on ectopic CALCIfication in FAhr’s Disease.
    Medical condition: Fahr’s disease or sondrome is a neurodegenerative disease in which all patients present with bilateral vessel associated calcifications in the basal ganglia in the absence of other secondary causes...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10059626 Fahr's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001514-38 Sponsor Protocol Number: V1-27/03/2020 Start Date*: 2020-08-06
    Sponsor Name:Fundació Clínic Recerca Biomèdica
    Full Title: Effects of Ospemifene on brain activation patterns in women with sexual interest-arousal disorders.
    Medical condition: Vulvovaginal Atrophy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012179-82 Sponsor Protocol Number: B0401005 Start Date*: 2010-01-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 07 06:39:47 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA